Journey Medical Corporation (DERM) Stock Analysis & Investment Frameworks
Journey Medical Corporation (DERM) stock analysis on Invetso. Review Journey Medical Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Journey Medical Corporation Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Journey Medical Corporation Key Financial Metrics
- Market Cap: $126.16M
- Revenue: $61.86M
- ROE: -20.23%
- ROIC: -5.22%
- Dividend Yield: N/A
About Journey Medical Corporation
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.